Psomagen

Psomagen

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17M

Overview

Psomagen is a well-established, US-based contract laboratory service provider specializing in multiomics technologies and data analysis. It differentiates itself through its dual CLIA/CAP accreditation, status as a certified service provider for leading technology platforms like 10x Genomics and Olink, and a collaborative, client-focused approach. The company serves a broad market from academic and biopharma research to clinical diagnostics, leveraging a wide portfolio of sequencing and analytical technologies to make cutting-edge omics accessible and affordable.

Genetics & Genomics

Technology Platform

Integrated ecosystem of third-party multiomics platforms (Illumina, PacBio, Oxford Nanopore, 10x Genomics, Olink, Bruker) with CLIA/CAP-accredited laboratory workflows and bioinformatics analysis services.

Funding History

2
Total raised:$17M
Series A$12M
Seed$5M

Opportunities

Strong growth driven by increasing adoption of multiomics and spatial biology in biopharma R&D and translational research.
Expansion of CLIA-certified services presents a significant opportunity as genomic applications move into clinical diagnostics and personalized medicine.
The trend towards outsourcing by academic and biotech clients provides a stable demand for accessible, high-quality contract services.

Risk Factors

High dependence on third-party technology vendors, exposing the company to platform obsolescence and changes in vendor agreements.
Intense competition in the genomics CRO market from large players and academic core facilities pressures pricing and margins.
Revenue is sensitive to cyclical funding in academia and biopharma R&D budgets.

Competitive Landscape

Psomagen competes in a fragmented but competitive market. Key competitors include large global CROs (e.g., Labcorp, Eurofins), specialized genomics service providers (e.g., Azenta, GENEWIZ), and university core facilities. Its differentiation lies in its broad multiomics portfolio, certified partner status with leading platforms, and dual CLIA/CAP accreditation for research-to-clinical support.